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ABSTRACT
Methicillin-susceptible Staphylococcus aureus
(MSSA) strains can produce superantigenic toxins
that may trigger a massive release of pro-inﬂam-
matory cytokines, which are involved in the onset
of septic shock. This 1-year prospective pilot study
assessed the role of the production of superanti-
genic toxins in the outcome of immunocompetent
patients hospitalised for community-acquired
MSSA bacteraemia. Thirty-seven patients were
enrolled, of whom 14 died in hospital. Fourteen
patients had septic shock, and the mortality rate in
this subgroup was 56%. Twenty-seven (73%)
isolates produced at least one superantigenic
toxin, but this did not inﬂuence the rate of
occurrence of septic shock or death.
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The high mortality rate associated with commu-
nity-acquired methicillin-susceptible Staphylococ-
cus aureus (MSSA) bacteraemia [1,2] appears to be
inﬂuenced by the occurrence of septic shock [1–3].
Superantigenic toxins can trigger a massive
release of pro-inﬂammatory cytokines, and these
are involved in the onset of septic shock [4–6]. In a
recent study, the presence of the enterotoxin A
gene (sea) was correlated with the severity of
infection [6]. However, the potential impact of the
production of superantigenic toxins by MSSA on
the rate of occurrence of septic shock and mor-
tality remains poorly understood [7].
Thepresentprospectiveobservational studywas
performed during a 12-month period in a 1280-bed
teaching hospital. All consecutive immunocompe-
tent patients aged >18 years who had community-
acquired MSSA bacteraemia were eligible. Patient
characteristics and their Sequential Organ Failure
Assessment (SOFA) scores [8] were recorded at
enrolment. Septic shock was deﬁned as a require-
ment for vasopressor therapy to maintain a mean
blood pressure of ‡80 mmHg. Initial antibiotic
therapy (delay in commencement, type and dose)
was assessed for each patient. All patients were
followed until hospital discharge or death.
The presence of genes for superantigenic
enterotoxins (SEA, SEB, SEC, SED, SEE, SEH,
SEG and SEI, and toxic shock syndrome toxin 1)
and Panton–Valentine leukocidin (PVL) was de-
tected by PCR as described previously [9]. As the
sed and sej genes are located on the same mobile
genetic element, sed-positive isolates were also
considered to be sej-positive. Similarly, as the seg,
sei, selm, seln and selo genes belong to the entero-
toxin gene cluster (egc), isolates that were positive
for the seg and sei genes were also considered to be
positive for the egc gene cluster. The superanti-
genic activity of each isolate was conﬁrmed by
testing lymphocyte activation by means of ﬂow-
cytometry as described previously [10].
Results for survivors and for patients who died
in hospital were compared. Qualitative variables
were expressed as numbers and percentages, and
were compared using the chi-square test or
Fisher’s exact test. Continuous variables were
expressed as means ± standard deviation, and
were compared using Student’s t-test or the
Mann–Whitney U-test. A multivariate analysis,
based on a multiple logistic regression (SAS
v.6.12; SAS Institute, Cary, NC, USA) was used
to identify independent risk-factors for hospital
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death. All risk-factors identiﬁed in the univariate
analysis with p £0.20 were integrated with
the production of superantigenic toxins in the
multiple logistic regression model. ORs and
95% CIs were calculated for each risk-factor.
During the study period, 161 patients were
admitted with MSSA bacteraemia and sepsis. Of
these, 124 were excluded because the origin of
bacteraemia was nosocomial (n = 78), or because
they were undergoing dialysis (n = 15) or were
immunosuppressed (n = 31). The mean SOFA
score of the remaining 37 patients was 4.3 ± 4.4
(range 0–14). Twenty-three (62%) patients sur-
vived, and the mean length of hospital stay was
45 ± 37 days. Fourteen (38%) patients died in
hospital after a mean interval of 16 ± 16 days
following admission. On the basis of a subjective
analysis of the clinical and biological data by two
authors (AD and AH), death was attributed to
MSSA bacteraemia for 11 patients, and to hepatic
failure secondary to liver ﬁbrosis for the three
remaining patients. Mean age, gender, pre-exist-
ing morbidity and origin of infection were similar
for survivors and non-survivors (Table 1). Initial
antibiotic therapy was appropriate for 33 (89%)
patients, with no difference between the study
groups.
Among the MSSA isolates from blood culture,
27 (73%) produced at least one superantigenic
toxin (one toxin, n = 3; two or more toxins, n = 24)
and three produced PVL. Isolates from 11 (79%) of
the 14 deceased patients produced at least one
superantigenic toxin, whereas 16 (70%) of the 23
patients who survived were infected by strains
that produced at least one superantigenic toxin
(OR 1.60, 95% CI 0.34–7.59, p 0.55). The superan-
tigenic toxins detected most frequently were
enterotoxins SEG and SEI, indicating the presence
of the egc gene cluster (Table 2). The distribution
of superantigenic toxins was similar in the two
study groups (Table 2). Fourteen patients in the
study population developed circulatory failure,
but superantigenic toxin production failed to
inﬂuence the rate of occurrence of septic shock
(OR 1.60, 95% CI 0.34–7.59, p 0.55). The SOFA
score was the only independent parameter asso-
ciated with hospital death (OR per additional
point 1.36, 95% CI 1.03–1.78, p 0.028).
In a study conducted in a heterogeneous popu-
lation with community- and hospital-acquired
infections or colonisation caused by MSSA and
methicillin-resistant Staphylococcus aureus, entero-
toxin A was identiﬁed more frequently in isolates
from patients who developed septic shock [6]. It
was speculated that enterotoxin A could trigger
the over-expression of inﬂammatory mediators
that may, in turn, lead to the development of septic
shock. In the present homogeneous, but limited,
study population, comprising patients with com-
munity- acquired MSSA bacteraemia, production
of superantigenic toxins failed to inﬂuence the rate
of occurrence of septic shock or subsequent death.
PVL was identiﬁed in only three of the 37 patients.
Previous studies have reported substantially high-
er proportions of MSSA strains that produce PVL,
albeit in different populations [12,13].
The mortality rate associated with S. aureus
bacteraemia is highly variable, ranging from 3.6%
to 83.3% [14], and is inﬂuenced by numerous
factors that include methicillin susceptibility, the
type of infection and the underlying disease [14–
17]. In the present study, the hospital mortality
Table 1. Characteristics of the study population and risk-
factors for methicillin-susceptible Staphylococcus aureus




n = 14 p
Age, years (range) 67 ± 15 (24–88) 59 ± 18 (32–84) 0.19
Male gender, n (%) 17 (74) 6 (43) 0.09
Medical history, n (%)
Diabetes mellitus 11 (48) 7 (50) 1
Anti-inﬂammatory drugs 5 (22) 1 (7) 0.38
Intravenous drug use 1 (4) 0 1
Chronic underlying diseasea 3 (13) 4 (29) 0.39
Origin of bacteraemia, n (%)
Skin infection 15 (65) 11 (79) 0.48
Bone ⁄ joint infection 5 (22) 1 (7) 0.38
Urinary tract infection 2 (9) 2 (14) 0.62
Lung infection 1 (4) 0 1
aChronic respiratory failure, chronic heart failure or hepatic cirrhosis with portal
hypertension, deﬁned according to Knaus et al. [11].
Table 2. Superantigenic toxin production by methicillin-
susceptible Staphylococcus aureus blood culture isolates in






One superantigenic toxin 16 (70) 11 (79) 0.71
Two or more superantigenic toxins 14 (61) 10 (71) 0.72
Enterotoxins
SEA 2 (9) 3 (21) 0.35
SEB 1 (4) 2 (14) 0.28
SEC 3 (13) 2 (14) 1
SED 2 (9) 2 (14) 0.60
SEE 0 0 –
SEG 13 (57) 8 (57) 1
SEH 1 (4) 2 (14) 0.54
SEI 15 (65) 8 (57) 0.73
TSST-1 5 (22) 0 0.13
PVL 2 (9) 1 (7) 1
TSST-1, toxic shock syndrome toxin 1; PVL, Panton–Valentine leukocidin.
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rate was as high as 38%, in keeping with reports
published previously [1], and the risk of death
increased with the number of organ dysfunctions,
as evaluated by the SOFA score [18].
In conclusion, community-acquired MSSA bac-
teraemia in immunocompetent patients is associ-
ated with a high mortality rate. In the present pilot
study, a large proportion (73%) of MSSA isolates
produced a superantigenic toxin. Nevertheless,
the production of superantigenic toxins failed to
inﬂuence the development of septic shock or
subsequent death. However, because of the lim-
ited number of patients included in the study, the
statistical power was limited, and these prelimin-
ary data should be interpreted with caution.
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